Bupivacaine for Post-Traumatic Headache

This trial tests a treatment for headaches that occur after a head injury, using a medication called bupivacaine. Researchers aim to determine if different strengths of this medication, delivered through a simple procedure called a nerve block (specifically, a bilateral greater occipital nerve block), can reduce the frequency of these headaches. Participants will receive one of three different doses of bupivacaine or a placebo (inactive treatment). Veterans who have experienced headaches at least twice a week for three months following a head injury, with no other identified cause, may be suitable candidates. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

Research shows that bupivacaine is usually well-tolerated for nerve blocks. This local anesthetic has been used for other types of pain relief. In past studies, patients who received bupivacaine for nerve blocks reported few serious side effects. Most often, mild reactions such as temporary numbness, dizziness, or mild soreness at the injection site occur.

Specific data on side effects for bupivacaine in greater occipital nerve blocks is not available. However, the trial aims to test the treatment's effectiveness and safety, indicating that earlier studies have found it reasonably safe.

Participants in this trial will receive different doses: 0.05% and 0.5%. These variations help determine how well each dose is tolerated. Bupivacaine already has FDA approval for other uses, supporting its general safety.

Most treatments for post-traumatic headaches typically involve oral medications like NSAIDs, triptans, or muscle relaxants. But the use of bupivacaine for this condition is unique because it involves a nerve block technique, specifically targeting the greater occipital nerves. This local anesthetic approach can directly reduce headache pain by numbing the nerves involved, potentially offering faster relief than oral medications. Researchers are excited as this method could minimize systemic side effects and provide a non-opioid alternative, addressing pain at the source with precision.

This trial will compare different doses of bupivacaine for blocking the greater occipital nerve to reduce headache pain. Studies have shown that using bupivacaine in this manner can effectively alleviate headache pain, with effects lasting several weeks. Specifically, patients have reported improvements in headache severity for up to six months after receiving these anesthetic injections. Additionally, researchers have found nerve blocks to be very effective for managing headaches caused by trauma. Overall, these findings suggest that bupivacaine nerve block could be a promising option for people suffering from post-traumatic headaches.¹²³⁴⁵